14th Aug 2020
With significant help from the fight against the Coronavirus, biotechnology stock and exchange-traded funds are setting torrid paces this year.
What happened: This year notwithstanding, one thing the biotechnology space has a history of is small stocks providing jaw-dropping gains. Even with that compelling history, only a small number of ETFs provide adequate exposure to small- and mid-cap biotech equities.
A new kid on the block, the Defiance Nasdaq Junior Biotechnology ETF, is broadening that group. IBBJ debuted on Tuesday and is the third ETF in the Defiance suite, though the issuer has a couple of more products in its pipeline.
Why It’s Important: The new IBBJ follows the Nasdaq Junior Biotechnology Index, the small stock offshoot of the widely followed Nasdaq Biotechnology Index. IBBJ’s underlying index only includes companies with market values of $5 billion or less at the time of inclusion.